PCRX
NASDAQPacira BioSciences Inc.
News · 26 weeks98-14%
2025-12-282026-06-21
Mix5790d
- Other24(42%)
- Insider15(26%)
- SEC Filings14(25%)
- Earnings2(4%)
- Leadership2(4%)
Latest news
25 items- INSIDERDirector Hirawat Samit was granted 6,405 shares (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSenior Vice President, Finance Riker Lauren sold $143,702 worth of shares (6,115 units at $23.50) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 62,284 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSEC Form 4 filed by Director Wiggans Thomas G4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Christie Christopher was granted 6,405 shares, increasing direct ownership by 38% to 23,059 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Young Alethia was granted 6,405 shares, increasing direct ownership by 56% to 17,798 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Yang Michael J. was granted 6,405 shares, increasing direct ownership by 48% to 19,798 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Bigal Marcelo was granted 6,405 shares, increasing direct ownership by 56% to 17,798 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Brege Laura was granted 6,405 shares, increasing direct ownership by 27% to 30,120 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Froimson Mark was granted 6,405 shares, increasing direct ownership by 32% to 26,541 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wiggans Thomas G3 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- PRPacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual MeetingBRISBANE, Calif., June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that based on the preliminary results of its 2026 Annual Meeting of Stockholders (the "Annual Meeting") provided by its proxy solicitor, D.F. King & Co., Inc., all three of Pacira's highly qualified director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – were elected to the Board of Directors. Frank D. Lee, chief executive officer, said, "On behalf of the board and executive leadership team, I would like to express o
- INSIDERSenior Vice President, Finance Riker Lauren covered exercise/tax liability with 3,187 shares, decreasing direct ownership by 4% to 68,399 units (SEC Form 4) to satisfy withholding tax4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERChief Medical Officer Slonin Jonathan covered exercise/tax liability with 4,728 shares, decreasing direct ownership by 2% to 218,912 units (SEC Form 4) to satisfy withholding obligation4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERChief Administrative Officer Williams Kristen sold $228,468 worth of shares (10,259 units at $22.27) as part of a pre-agreed trading plan and covered exercise/tax liability with 8,528 shares, decreasing direct ownership by 10% to 167,062 units (SEC Form 4) to satisfy withholding obligation4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual MeetingElection of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward MomentumLeading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not WarrantedBRISBANE, Calif., June 4, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued a reminder to all Pacira stockholders to vote the BLUE proxy card "FOR" each of Pacira's three highly qualified director nominees in advance of the Company's upcoming 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2026. Ahea
- SECSEC Form 144 filed by Pacira BioSciences Inc.144 - Pacira BioSciences, Inc. (0001396814) (Subject)
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director NomineesISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change"BRISBANE, Calif., June 1, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. ("ISS") has recommended that Pacira stockholders vote "FOR" each of Pacira's three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – and "AGAINST" all three of DOMA Perpetual Ca
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Pacira's Director NomineesBRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that leading independent proxy advisory firm Glass Lewis & Co., LLC ("Glass Lewis") has recommended that Pacira stockholders vote "FOR" each of Pacira's three director nominees – Christopher Christie, Samit Hirawat, MD and Thomas Wiggans – and "AGAINST" all three of DOMA Perpetual Capital Management LLC's ("DOMA Perpetual" or "DOMA")1 nominees on the BLUE proxy card ahead of the Company's 2026 Annual Meeting of Stockholders (the "Annual
- PRDOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTIONPACIRA'S STOCK PRICE IS DOWN FOR EVERY RECENT PERIOD: 10 YEAR, 5 YEAR, 3 YEAR, 2 YEAR, ONE YEAR, AND YEAR-TO-DATEDOMA BELIEVES MANAGEMENT IS MISLEADING STAKEHOLDERS REGARDING ITS PATENT PROTECTION AND MINIMIZING THE POTENTIAL BUSINESS-DESTROYING CONSEQUENCES OF ANOTHER LEGAL LOSS, CONSTITUTING GROSS NEGLIGENCEDOMA CONTENDS THE BOARD IS REFUSING TO EXPLORE A SALE BECAUSE DIRECTORS DO NOT WANT TO LOSE THEIR JOBS, PUTTING THEIR INTERESTS AHEAD OF SHAREHOLDERSMIAMI, May 28, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management ("DOMA Perpetual") is a fundamentals-based, value-oriented asset management firm, which, together with its affiliates (collectively, "DOMA" or "we"), beneficially owns ap
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified NomineesClarifies DOMA's Inaccuracies and the Reality of Pacira' Efforts to Strengthen its Market Position Urges Stockholders to Vote "FOR" the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following communication with important facts stockholders should know to help protect their Pacira investment. The complete text of the letter mailed to stockholders is as follows: May 27, 2026 Dear Pacira Stockholders, A
- PRAfter Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast InsteadConexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea
PCRX FAQ
7 questionsWhat does Pacira BioSciences Inc. do?
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver...Where does PCRX stock trade?
Pacira BioSciences Inc. (PCRX) is listed on NASDAQ.What sector and industry is PCRX in?
Pacira BioSciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pacira BioSciences Inc. go public?
Pacira BioSciences Inc. (PCRX) completed its IPO in 2011.What are analysts saying about PCRX?
Pacira BioSciences Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $2700.00 price target on 2025-12-09. Recent price targets range from $800.00 to $3000.00.What companies are similar to PCRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PCRX side-by-side with any of them on Quantisnow.How can I track PCRX on Quantisnow?
Quantisnow aggregates Pacira BioSciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PCRX to receive live email and push alerts on every new disclosure.